title: Endovascular recanalization of basilar artery occlusion 80 days after symptom onset.
abstract: OBJECTIVE
  Acute basilar artery occlusion portends high risk of stroke and death. Thrombolysis or endovascular therapy has been limited to patients who present within hours of symptom onset. Without recanalization, acute basilar artery occlusion almost always results in death or severe disability.
  
  
  METHODS
  We report a case of basilar artery occlusion and successful endovascular recanalization 80 days after symptom onset.
  
  
  CONCLUSIONS
  Endovascular therapy can be feasible and safe for symptomatic basilar artery occlusion at chronic stage.
authors.affiliation: Department of Neurology, University of California, Irvine, CA, USA. wyu@yahoo.com
authors.forename: Wengui
authors.initials: W
authors.lastname: Yu
authors.forename: Varoujan
authors.initials: V
authors.lastname: Kostanian
authors.forename: Mark
authors.initials: M
authors.lastname: Fisher
mesh_terms: D000077284:Abciximab; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D001488:Basilar Artery / Q000187:drug effects* / Q000503:physiopathology / Q000601:surgery*; D002533:Cerebral Angiography; D002908:Chronic Disease; D005343:Fibrinolytic Agents / Q000627:therapeutic use; D006261:Headache / Q000209:etiology; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000627:therapeutic use; D008279:Magnetic Resonance Imaging; D008297:Male; D008875:Middle Aged; D010291:Paresis / Q000209:etiology; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use; D015607:Stents / Q000592:standards*; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000627:therapeutic use; D014057:Tomography, X-Ray Computed; D016896:Treatment Outcome; D014656:Vascular Surgical Procedures / Q000295:instrumentation / Q000379:methods*; D014715:Vertebrobasilar Insufficiency / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D015354:Vision, Low / Q000209:etiology
chemical_list: D000911:Antibodies, Monoclonal; D005343:Fibrinolytic Agents; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D010959:Tissue Plasminogen Activator; D000077284:Abciximab